Ellen L Weisberg (Ellen Weisberg)

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 15

Top Venues

Cell death and differentiation

Leukemia

Journal of cellular and molecular medicine

Biochemistry

This page only lists publications with an associated author ORCID identifier.

Publications

Swati Garg, Wei Ni, Basudev Chowdhury, Ellen L Weisberg, Martin Sattler, James D Griffin
BRD9 regulates normal human hematopoietic stem cell function and lineage differentiation. Cell death and differentiation 31 (7) (2024)
Swati Garg, Wei Ni, Basudev Chowdhury, Ellen L Weisberg, Martin Sattler, James D Griffin
BRD9 regulates normal human hematopoietic stem cell function and lineage differentiation. Cell death and differentiation 31 (7) (2024)
Swati Garg, Wei Ni, Basudev Chowdhury, Ellen L Weisberg, Martin Sattler, James D Griffin
BRD9 regulates normal human hematopoietic stem cell function and lineage differentiation. Cell death and differentiation 31 (7) (2024)
Swati Garg, Wei Ni, Basudev Chowdhury, Ellen L Weisberg, Martin Sattler, James D Griffin
BRD9 regulates normal human hematopoietic stem cell function and lineage differentiation. Cell death and differentiation (2024)
Ellen L Weisberg, Basudev Chowdhury, Chengcheng Meng, Abigail E Case, Wei Ni, Swati Garg, Martin Sattler, Abdel Kareem Azab, Abdel Kareem Azab, Barbara Muz, Dana Sanchez, Anthia Toure, Richard M Stone, Ilene Galinsky, Eric Winer, Scott Gleim, Sofia Gkountela, Alexia Kedves, Edmund Harrington, Tinya Abrams, Thomas Zoller, Andrea Vaupel, Paul Manley, Michael Faller, BoYee Chung, Xin Chen, Philipp Busenhart, Christine Stephan, Keith Calkins, Debora Bonenfant, Claudio R Thoma, William Forrester, James D Griffin
BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma. Blood cancer journal 12 (7) (2022)
RuthMabel Boytz, Mikołaj Słabicki, Sita Ramaswamy, J J Patten, Charles Zou, Chengcheng Meng, Brett L Hurst, Jinhua Wang, Radosław P Nowak, Priscilla L Yang, Martin Sattler, Richard M Stone, James D Griffin, Nathanael S Gray, Suryaram Gummuluru, Robert A Davey, Ellen L Weisberg
Anti-SARS-CoV-2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID-19 therapy. Journal of medical virology (2022)
Jing Yang, Ellen L Weisberg, Shuang Qi, Wei Ni, Husheng Mei, Zuowei Wang, Chengcheng Meng, Shengzhe Zhang, Mingqi Hou, Ziping Qi, Aoli Wang, Yunyun Jiang, Zongru Jiang, Tao Huang, Qingwang Liu, Robert S Magin, Laura Doherty, Wenchao Wang, Jing Liu, Sara J Buhrlage, Qing-Song Liu, James D Griffin
Inhibition of the deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2. Leukemia 36 (4) (2022)
Jing Yang, Ellen L Weisberg, Xiaoxi Liu, Robert S Magin, Wai Cheung Chan, Bin Hu, Nathan J Schauer, Shengzhe Zhang, Ilaria Lamberto, Laura Doherty, Chengcheng Meng, Martin Sattler, Lucia Cabal-Hierro, Eric Winer, Richard Stone, Jarrod A Marto, James D Griffin, Sara J Buhrlage
Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2. Leukemia (2021)
Ellen L Weisberg, Chengcheng Meng, Abigail E Case, Hong L Tiv, Prafulla C Gokhale, Anthia A Toure, Sara Buhrlage, Xiaoxi Liu, Jinhua Wang, Nathanael Gray, Richard Stone, Sophia Adamia, Eric Winer, Martin Sattler, James D Griffin
The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations. Journal of cellular and molecular medicine 24 (3) (2020)
Ellen L Weisberg, Chengcheng Meng, Abigail E Case, Hong L Tiv, Prafulla C Gokhale, Sara J Buhrlage, Jing Yang, Xiaoxi Liu, Jinhua Wang, Nathanael Gray, Sophia Adamia, Martin Sattler, Richard Stone, James D Griffin
Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia. Journal of cellular and molecular medicine 24 (5) (2020)
Ellen L Weisberg, Alexander Parent, Priscilla L Yang, Martin Sattler, Qingsong Liu, Qingwang Liu, Jinhua Wang, Chengcheng Meng, Sara J Buhrlage, Nathanael Gray, James D Griffin
Repurposing of Kinase Inhibitors for Treatment of COVID-19. Pharmaceutical research 37 (9) (2020)
Ellen L Weisberg, Chengcheng Meng, Abigail E Case, Martin Sattler, Hong L Tiv, Prafulla C Gokhale, Sara J Buhrlage, Xiaoxi Liu, Jing Yang, Jinhua Wang, Nathanael Gray, Richard M Stone, Sophia Adamia, Patrice Dubreuil, Sebastien Letard, James D Griffin
Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. British journal of haematology 187 (4) (2019)
Xiaofei Liang, Beilei Wang, Cheng Chen, Aoli Wang, Chen Hu, Fengming Zou, Kailin Yu, Qingwang Liu, Feng Li, Zhenquan Hu, Tingting Lu, Junjie Wang, Li Wang, Ellen L Weisberg, Lili Li, Ruixiang Xia, Wenchao Wang, Tao Ren, Jian Ge, Jing Liu, Qing-Song Liu
Discovery of N-(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid Leukemia. Journal of medicinal chemistry 62 (2) (2019)
Ellen L Weisberg, Chengcheng Meng, Abigail Case, Martin Sattler, Hong L Tiv, Prafulla C Gokhale, Sara Buhrlage, Jinhua Wang, Nathanael S Gray, Richard Stone, Suiyang Liu, Shripad V Bhagwat, Ramon V Tiu, Sophia Adamia, James D Griffin
Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. Leukemia 34 (2) (2019)
Paul W Manley, Ellen L Weisberg, Martin Sattler, James D Griffin
Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological MalignanciesPublished as part of the Biochemistry series "Biochemistry to Bedside". Biochemistry 57 (5) (2017)

Ellen L Weisberg.css-eqlu8i{font-size:small;padding-left:4px;} (Ellen Weisberg)

Publication Activity (10 Years)

Top Topics

Top Venues

Ellen L Weisberg (Ellen Weisberg)